1498060-48-2

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 345-35-7 2-fluorobenzyl chloride 

Downstream Products

• 1630013-14-7 4-butyl-5-(4-(2-fluorobenzyloxy)phenyl)-2H-1,2,4-triazole-3(4H)-one 
• 1630012-39-3 [4‐(2‐fluorobenzyloxy)benzoyl]hydrazine 
• 1630012-49-5 C₁₅H₁₁FN₂O₃ 
• 1630012-64-4 C₁₉H₂₂FN₃O₃ 

Relevant academic research and scientific papers

Synthesis and characterization of novel radiofluorinated probes for positron emission tomography imaging of monoamine oxidase B

Monoamine oxidase B (MAO-B), predominantly expressed in glial cells, plays an important role in neurotransmitter regulation, and MAO-B activity relates to several neuronal diseases. Here, we aimed to develop a radiofluorinated MAO-B imaging probe based on the structure of a selective MAO-B inhibitor, MD-230254. We synthesized and evaluated a series of compounds in vitro and in vivo. A series of fluorinated analogs of MD-230254 were synthesized and evaluated for inhibitory potency and selectivity toward MAO-B. 5-[4-(2-[18F]Fluorobenzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3H)-one (2-[18F]FBPO) was synthesized from a corresponding tributylstannyl precursor and [18F]CH3COOF. Biodistribution after intravenous injection of 2-[18F]FBPO was evaluated in male ddY mice with or without pretreatment by inhibitors. Among the compounds synthesized and evaluated, 2-FBPO showed high inhibitory potency and selectivity toward MAO-B comparable with MD-230254. 2-[18F]FBPO was successfully synthesized by an electrophilic reaction with a high radiochemical purity of more than 99%. 2-[18F]FBPO was efficiently taken up by the brain and showed rapid blood clearance, which provided a brain/blood radioactivity ratio of 3.7 at 90 minutes postinjection. The brain radioactivity was significantly decreased by pretreatment with an MAO-B selective inhibitor. The great potential of 2-[18F]FBPO as an MAO-B imaging probe, applicable to a variety of diseases, is indicated.

Synthesis and anticonvulsant activity evaluation of 4-butyl-5-(4- alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones

A series of 4-butyl-5-(4-alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones (6a-6u) was designed and synthesized. The anticonvulsant effects and neurotoxicity of the compounds were evaluated with maximal electroshock test and rotarod test. Among the synthetic compounds, 4-butyl-5-(4-(2-fluorinebenzyl)phenyl)-2H-1,2,4- triazole-3 (4H)-one (6k) was the most potent with ED50 value of 27.4 mg/kg and protective index (PI = TD50/ED50) value of 12.0. Besides the anti-MES efficacy, the potency of compound 6k against seizures induced by pentylenetetrazole (PTZ), 3-mercaptopropionic acid (3-MP), and bicuculline (BIC) was also established, which suggested that the mechanisms of action including enhancing of GABAergic activity might be involved in its anticonvulsant activity.